Clinical Trials Logo

Filter by:
NCT ID: NCT03208127 Terminated - Hepatitis C Clinical Trials

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Start date: November 21, 2017
Phase: Phase 4
Study type: Interventional

This is a single center study for the donation of Hepatitis C Virus (HCV)-positive livers to HCV negative recipient patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.

NCT ID: NCT03208023 Terminated - Clinical trials for Fluid Responsiveness

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

RESIPI
Start date: October 9, 2017
Phase: N/A
Study type: Interventional

This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.

NCT ID: NCT03207867 Terminated - Pancreatic Cancer Clinical Trials

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Start date: August 28, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.

NCT ID: NCT03207815 Terminated - Clinical trials for Noninfectious Uveitis

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

HUMBOLDT
Start date: July 26, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by Week 24.

NCT ID: NCT03207646 Terminated - Clinical trials for Coronary Artery Disease

Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease

smartGUIDE
Start date: July 19, 2017
Phase: N/A
Study type: Interventional

This study evaluates a smartphone-based cardiac rehabilitation program in adults with coronary artery disease. Half of patients will participate in a smartphone-based cardiac rehabilitation program while the other half will receive standard-of-care.

NCT ID: NCT03207399 Terminated - Clinical trials for Hepatitis C, Chronic

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Start date: September 15, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate whether treatment with Epclusa (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C infection is feasible, safe and effective at curing HCV.

NCT ID: NCT03207256 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Start date: August 9, 2017
Phase: Phase 2
Study type: Interventional

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

NCT ID: NCT03206788 Terminated - Cystic Fibrosis Clinical Trials

Losartan and Inflammation in Cystic Fibrosis

Start date: November 11, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the study is to examine if a specific drug called losartan (Cozaar ®), generally used to treat high blood pressure and to protect kidneys from damage in patients suffering from Diabetes Mellitus, will have any effect on the nasal inflammation in patients with cystic fibrosis (CF). The study will be performed at the Pulmonary Division at the University of Miami, Cincinnati Children's Medical Hospital Center, University of Kansas Medical Center and University of Alabama-Birmingham.

NCT ID: NCT03206736 Terminated - Obesity, Morbid Clinical Trials

Loop Duodenal Switch: Outcomes at One Year

Start date: August 9, 2018
Phase: N/A
Study type: Interventional

The biliopancreatic diversion and duodenal switch (BPD-DS) is an accepted and published type of bariatric surgery in the United States. The BPD-DS procedure produces the most weight loss of any bariatric surgery commonly performed but has the highest risk of malnutrition and gastrointestinal side effects. The loop duodenal switch (L-DS) is a bariatric surgery which has been modified from a biliopancreatic diversion and duodenal switch to maintain excellent weight loss while possibly reducing side effects. The surgical modifications in this procedure include reducing the number of intestinal reconnections from two to one and reducing the amount of small intestine which is bypassed. The L-DS operation is considered experimental by the American Society of Metabolic and Bariatric Surgery as long-term data in large numbers of patients is not available for weight loss or side effects. The purpose of this study is to examine weight loss and other outcomes in the L-DS operation up to 1 year after the procedure. Study participants will be seen in the clinic at 2 and 6 weeks, and 3, 6, 9, and 12 months per the bariatric surgery center protocol. As part of these normally scheduled visits, weight loss and health status will be recorded. Labs will be checked at 3, 6, and 12 months for nutritional status. A survey to reassess health-related quality of life and gastrointestinal symptoms will be performed at 3 months, 6 months and 12 months.

NCT ID: NCT03206463 Terminated - Bipolar Disorder Clinical Trials

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

THC-BD
Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the acute cognitive and psychophysiological effects of the main psychoactive constituent of cannabis, 9-delta-tetrahydrocannabinol (THC) in individuals with euthymic bipolar disorder (BD), and to begin probing the mechanisms that may underlie its effects in this illness. This study is expected to contribute to a better characterization of specific effects of THC in individuals with BD compared to healthy controls (HC).